Jeevanandam J, Chan YS, Danquah MK. Nano-formulations of medicine: current developments, influence and challenges. Biochimie. 2016;128–129:99–112.
Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug supply units. J Management Launch. 2001;70(1–2):1–20.
Erdoğar N, Akkın S, Bilensoy E. Nanocapsules for drug supply: an up to date evaluation of the final decade. Current Pat Drug Deliv Formul. 2018;12(4):252–66.
Miguel RDA, Hirata AS, Jimenez PC, et al. Past formulation: contributions of nanotechnology for translation of anticancer pure merchandise into new medicine. Pharmaceutics. 2022;14(8):1772.
Gregoriadis G, Ryman BE. Liposomes as carriers of enzymes or medicine: a brand new method to the remedy of storage illnesses. Biochem J. 1971;124(5):58p.
Stone NR, Bicanic T, Salim R, et al. Liposomal amphotericin B (AmBisome(®)): a evaluation of the pharmacokinetics, pharmacodynamics, medical expertise and future instructions. Medicine. 2016;76(4):485–500.
Porche DJ. Liposomal doxorubicin (Doxil). J Assoc Nurses AIDS Care. 1996;7(2):55–9.
Gradishar WJ, Tjulandin S, Davidson N, et al. Part III trial of nanoparticle albumin-bound paclitaxel in contrast with polyethylated castor oil-based paclitaxel in ladies with breast most cancers. J Clin Oncol. 2005;23(31):7794–803.
Lee KS, Chung HC, Im SA, et al. Multicenter part II trial of genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in sufferers with metastatic breast most cancers. Breast Most cancers Res Deal with. 2008;108(2):241–50.
Alfayez M, Kantarjian H, Kadia T, et al. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020;61(2):288–97.
Hoy SM. Patisiran: first world approval. Medicine. 2018;78(15):1625–31.
Duggan S. Caplacizumab: first world approval. Medicine. 2018;78(15):1639–42.
Teo SP. Evaluate of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract. 2022;35(6):947–51.
Hargreaves R, Ferreira JC, Hughes D, et al. Growth of aprepitant, the primary neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann NY Acad Sci. 2011;1222:40–8.
Khan O, Chaudary N. Using Amikacin liposome inhalation suspension (Arikayce) within the remedy of refractory nontuberculous mycobacterial lung illness in adults. Drug Des Devel Ther. 2020;14:2287–94.
Dean AQ, Luo S, Twomey JD, et al. Concentrating on most cancers with antibody-drug conjugates: guarantees and challenges. MAbs. 2021;13(1):1951427.
Nelemans LC, Gurevich L. Drug supply with polymeric nanocarriers-cellular uptake mechanisms. Supplies. 2020;13(2):1.
Alqosaibi AI. Nanocarriers for anticancer medicine: challenges and views. Saudi J Biol Sci. 2022;29(6): 103298.
Ghanbari-Movahed M, Kaceli T, Mondal A, et al. Current advances in improved anticancer efficacies of camptothecin nano-formulations: a scientific evaluation. Biomedicines. 2021;9(5):1.
Kubik T, Bogunia-Kubik Okay, Sugisaka M. Nanotechnology on obligation in medical functions. Curr Pharm Biotechnol. 2005;6(1):17–33.
Sinha R, Kim GJ, Nie S, et al. Nanotechnology in most cancers therapeutics: bioconjugated nanoparticles for drug supply. Mol Most cancers Ther. 2006;5(8):1909–17.
Elzoghby AO, Abdelmoneem MA, Hassanin IA, et al. Lactoferrin, a multi-functional glycoprotein: energetic therapeutic, drug nanocarrier & focusing on ligand. Biomaterials. 2020;263: 120355.
Miao D, Jiang M, Liu Z, et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma remedy. Mol Pharm. 2014;11(1):90–101.
Godlewska M, Majkowska-Pilip A, Stachurska A, et al. Voltammetric and organic research of folate-targeted non-lamellar lipid mesophases. Electrochim Acta. 2019;299:1–11.
Wei D, Solar Y, Zhu H, et al. Stimuli-responsive polymer-based nanosystems for most cancers theranostics. ACS Nano. 2023;17(23):23223–61.
Lin X, Track X, Zhang Y, et al. Multifunctional theranostic nanosystems enabling photothermal-chemo mixture remedy of triple-stimuli-responsive drug launch with magnetic resonance imaging. Biomater Sci. 2020;8(7):1875–84.
Chen L, Hong W, Ren W, et al. Current progress in focused supply vectors primarily based on biomimetic nanoparticles. Sign Transduct Goal Ther. 2021;6(1):225.
Fang RH, Kroll AV, Gao W, et al. Cell membrane coating nanotechnology. Adv Mater. 2018;30(23): e1706759.
Han X, Shen S, Fan Q, et al. Pink blood cell-derived nanoerythrosome for antigen supply with enhanced most cancers immunotherapy. Sci Adv. 2019;5(10):eaaw6870.
Parodi A, Quattrocchi N, van de Ven AL, et al. Artificial nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like capabilities. Nat Nanotechnol. 2013;8(1):61–8.
Chen Z, Zhao P, Luo Z, et al. Most cancers cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal remedy. ACS Nano. 2016;10(11):10049–57.
Xiong J, Wu M, Chen J, et al. Most cancers-erythrocyte hybrid membrane-camouflaged magnetic nanoparticles with enhanced photothermal-immunotherapy for ovarian most cancers. ACS Nano. 2021;15(12):19756–70.
Kao CY, Papoutsakis ET. Extracellular vesicles: exosomes, microparticles, their components, and their targets to allow their biomanufacturing and medical functions. Curr Opin Biotechnol. 2019;60:89–98.
Chung YH, Cai H, Steinmetz NF. Viral nanoparticles for drug supply, imaging, immunotherapy, and theranostic functions. Adv Drug Deliv Rev. 2020;156:214–35.
Zhao Y, Li A, Jiang L, et al. Hybrid membrane-coated biomimetic nanoparticles (HM@BNPs): a multifunctional nanomaterial for biomedical functions. Biomacromol. 2021;22(8):3149–67.
Pitchaimani A, Nguyen TDT, Aryal S. Pure killer cell membrane infused biomimetic liposomes for focused tumor remedy. Biomaterials. 2018;160:124–37.
Cheng S, Xu C, Jin Y, et al. Synthetic mini dendritic cells enhance T cell-based immunotherapy for ovarian most cancers. Adv Sci. 2020;7(7):1903301.
Mukker JK, Singh RSP. Pharmacokinetic modeling in nano-formulations: idea, implementation and challenges. Curr Pharm Des. 2018;24(43):5175–80.
Chopra A. Cy5.5-Conjugated glycol chitosan-5β-cholanic acid nanoparticles. In Molecular Imaging and Distinction Agent Database (MICAD). Bethesda (MD): Nationwide Middle for Biotechnology Info (US); 2004
Wang M, Thanou M. Concentrating on nanoparticles to most cancers. Pharmacol Res. 2010;62(2):90–9.
Belyaev IB, Griaznova OY, Yaremenko AV, et al. Past the EPR impact: Intravital microscopy evaluation of nanoparticle drug supply to tumors. Adv Drug Deliv Rev. 2025;219: 115550.
Wu X, Hu JJ, Yoon J. Cell membrane as a promising therapeutic goal: from supplies design to biomedical functions. Angew Chem Int Ed Engl. 2024;63(18): e202400249.
Zou D, Wu Z, Yi X, et al. Nanoparticle elasticity regulates the formation of cell membrane-coated nanoparticles and their nano-bio interactions. Proc Natl Acad Sci USA. 2023;120(1): e2214757120.
Walkey CD, Olsen JB, Guo H, et al. Nanoparticle measurement and floor chemistry decide serum protein adsorption and macrophage uptake. J Am Chem Soc. 2012;134(4):2139–47.
Li Y, Kröger M, Liu WK. Form impact in mobile uptake of PEGylated nanoparticles: comparability between sphere, rod, dice and disk. Nanoscale. 2015;7(40):16631–46.
Parakhonskiy B, Zyuzin MV, Yashchenok A, et al. The affect of the dimensions and side ratio of anisotropic, porous CaCO3 particles on their uptake by cells. J Nanobiotechnol. 2015;13:53.
Dong N, Liu Z, He H, et al. “Hook&Loop” multivalent interactions primarily based on disk-shaped nanoparticles strengthen energetic focusing on. J Management Launch. 2023;354:279–93.
Nguyen LNM, Lin ZP, Sindhwani S, et al. The exit of nanoparticles from strong tumours. Nat Mater. 2023;22(10):1261–72.
Liu J, Zhou Y, Lyu Q, et al. Focused protein supply primarily based on stimuli-triggered nanomedicine. Exploration. 2024;4(3):20230025.
Chen X, Fan X, Zhang Y, et al. Cooperative coordination-mediated multi-component self-assembly of “all-in-one” nanospike theranostic nano-platform for MRI-guided synergistic remedy in opposition to breast most cancers. Acta Pharm Sin B. 2022;12(9):3710–25.
Jeevanandam J, Barhoum A, Chan YS, et al. Evaluate on nanoparticles and nanostructured supplies: historical past, sources, toxicity and laws. Beilstein J Nanotechnol. 2018;9:1050–74.
Deng Okay, Luo Z, Tan L, et al. Self-assembly of anisotropic nanoparticles into purposeful superstructures. Chem Soc Rev. 2020.
Li J, Jia X. Photograph-controlled self-assembly of nanoparticles: a promising technique for growth of novel buildings. Nanomaterials. 2023;13:18.
Cheng S, Grest GS. Dispersing Nanoparticles in a Polymer Movie by way of Solvent Evaporation. ACS Macro Lett. 2016;5(6):694–8.
Iqbal M, Zafar N, Fessi H, et al. Double emulsion solvent evaporation methods used for drug encapsulation. Int J Pharm. 2015;496(2):173–90.
Mosayebi J, Kiyasatfar M, Laurent S. Synthesis, functionalization, and design of magnetic nanoparticles for theranostic functions. Adv Healthc Mater. 2017;6(23):1.
Devalapally H, Shenoy D, Little S, et al. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted supply of hydrophobic medicine: half 3. Therapeutic efficacy and security research in ovarian most cancers xenograft mannequin. Most cancers Chemother Pharmacol. 2007;59(4):477–84.
Bertrand N, Wu J, Xu X, et al. Most cancers nanotechnology: the influence of passive and energetic focusing on within the period of contemporary most cancers biology. Adv Drug Deliv Rev. 2014;66:2–25.
Maeda H. Towards a full understanding of the EPR impact in major and metastatic tumors in addition to points associated to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.
Shi J, Kantoff PW, Wooster R, et al. Most cancers nanomedicine: progress, challenges and alternatives. Nat Rev Most cancers. 2017;17(1):20–37.
Cornu R, Béduneau A, Martin H. Affect of nanoparticles on liver tissue and hepatic capabilities: a evaluation. Toxicology. 2020;430: 152344.
Önal Acet B, Gül D, Stauber RH, et al. A evaluation for uncovering the “protein-nanoparticle alliance”: implications of the protein corona for biomedical functions. Nanomaterials. 2024;14:10.
Chen F, Wang G, Griffin JI, et al. Complement proteins bind to nanoparticle protein corona and endure dynamic trade in vivo. Nat Nanotechnol. 2017;12(4):387–93.
Fröhlich E. Mobile elimination of nanoparticles. Environ Toxicol Pharmacol. 2016;46:90–4.
Hoshyar N, Grey S, Han H, et al. The impact of nanoparticle measurement on in vivo pharmacokinetics and mobile interplay. Nanomedicine. 2016;11(6):673–92.
Poon W, Zhang YN, Ouyang B, et al. Elimination pathways of nanoparticles. ACS Nano. 2019;13(5):5785–98.
Zhang YN, Poon W, Tavares AJ, et al. Nanoparticle-liver interactions: mobile uptake and hepatobiliary elimination. J Management Launch. 2016;240:332–48.
Model W, Noorlander CW, Giannakou C, et al. Nanomedicinal merchandise: a survey on particular toxicity and uncomfortable side effects. Int J Nanomedicine. 2017;12:6107–29.
Stone V, Johnston H, Schins RP. Growth of in vitro methods for nanotoxicology: methodological concerns. Crit Rev Toxicol. 2009;39(7):613–26.
Shiraishi Okay, Yokoyama M. Toxicity and immunogenicity issues associated to PEGylated-micelle provider methods: a evaluation. Sci Technol Adv Mater. 2019;20(1):324–36.
Chen J, Mao L, Jiang Y, et al. Revealing the In Situ habits of aggregation-induced emission nanoparticles and their biometabolic results by way of mass spectrometry imaging. ACS Nano. 2023;17(5):4463–73.
Portilho FL, Helal-Neto E, Cabezas SS, et al. Magnetic core mesoporous silica nanoparticles doped with dacarbazine and labelled with 99mTc for early and differential detection of metastatic melanoma by single photon emission computed tomography. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1080–7.
Li P, Wang D, Hu J, et al. The function of imaging in focused supply of nanomedicine for most cancers remedy. Adv Drug Deliv Rev. 2022;189: 114447.
Wang D, Pan Y, Chen W, et al. Nanodrugs focusing on key elements of ferroptosis regulation for enhanced remedy of osteoarthritis. Adv Sci. 2025;12(11): e2412817.
The L. GLOBOCAN 2018: counting the toll of most cancers. Lancet. 2018;392(10152):985.
Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining focused and standard most cancers remedy with immunotherapy. Nat Rev Most cancers. 2017;17(5):286–301.
Romanini A, Tanganelli L, Carnino F, et al. First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the remedy of superior epithelial ovarian most cancers sufferers. Gynecol Oncol. 2003;89(3):354–9.
Wu Q, Yang Z, Nie Y, et al. Multi-drug resistance in most cancers chemotherapeutics: mechanisms and lab approaches. Most cancers Lett. 2014;347(2):159–66.
Brannon-Peppas L, Blanchette JO. Nanoparticle and focused methods for most cancers remedy. Adv Drug Deliv Rev. 2004;56(11):1649–59.
Janjic A, Cayoren M, Akduman I, et al. SAFE: a novel microwave imaging system design for breast most cancers screening and early detection-clinical analysis. Diagnostics. 2021;11:3.
Kuai R, Li D, Chen YE, et al. Excessive-density lipoproteins: nature’s multifunctional nanoparticles. ACS Nano. 2016;10(3):3015–41.
Wang X, Lin L, Liu R, et al. Anisotropy in form and ligand‐conjugation of hybrid nanoparticulates manipulates the mode of bio–nano interplay and its consequence. 2017;27(31):1700406.
Zheng G, Chen J, Li H, et al. Rerouting lipoprotein nanoparticles to chose alternate receptors for the focused supply of most cancers diagnostic and therapeutic brokers. Proc Natl Acad Sci USA. 2005;102(49):17757–62.
Bariwal J, Ma H, Altenberg GA, et al. Nanodiscs: a flexible nanocarrier platform for most cancers prognosis and remedy. Chem Soc Rev. 2022;51(5):1702–28.
Feng H, Wang M, Wu C, et al. Excessive scavenger receptor class B kind I expression is expounded to tumor aggressiveness and poor prognosis in lung adenocarcinoma: a STROBE compliant article. Medication. 2018;97(13): e0203.
Tang J, Kuai R, Yuan W, et al. Impact of measurement and pegylation of liposomes and peptide-based artificial lipoproteins on tumor focusing on. Nanomedicine. 2017;13(6):1869–78.
Chen W, Jarzyna PA, van Tilborg GA, et al. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a flexible and multimodal tumor focusing on molecular imaging probe. Faseb J. 2010;24(6):1689–99.
Li W, Yu H, Ding D, et al. Chilly atmospheric plasma and iron oxide-based magnetic nanoparticles for synergetic lung most cancers remedy. Free Radical Biol Med. 2019;130:71–81.
Gao P, Mei C, He L, et al. Designing multifunctional cancer-targeted nanosystem for magnetic resonance molecular imaging-guided theranostics of lung most cancers. Drug Deliv. 2018;25(1):1811–25.
Tiwari N, Gheldof A, Tatari M, et al. EMT as the final word survival mechanism of most cancers cells. Semin Most cancers Biol. 2012;22(3):194–207.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for most cancers. Nat Rev Mol Cell Biol. 2019;20(2):69–84.
Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: sure, no, possibly? Curr Opin Cell Biol. 2016;43:7–13.
Ang HL, Mohan CD, Shanmugam MK, et al. Mechanism of epithelial-mesenchymal transition in most cancers and its regulation by pure compounds. Med Res Rev. 2023;43(4):1141–200.
Balakrishnan S, Bhat FA, Raja Singh P, et al. Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness by way of EGFR/VEGFR-2-mediated pathway in breast most cancers. Cell Prolif. 2016;49(6):678–97.
Agarwalla P, Mukherjee S, Sreedhar B, et al. Glucocorticoid receptor-mediated supply of nano gold-withaferin conjugates for reversal of epithelial-to-mesenchymal transition and tumor regression. Nanomedicine. 2016;11(19):2529–46.
Baghi N, Bakhshinejad B, Keshavarz R, et al. Dendrosomal nanocurcumin and exogenous p53 can act synergistically to elicit anticancer results on breast most cancers cells. Gene. 2018;670:55–62.
Kumari M, Ray L, Purohit MP, et al. Curcumin loading potentiates the chemotherapeutic efficacy of selenium nanoparticles in HCT116 cells and Ehrlich’s ascites carcinoma bearing mice. Eur J Pharm Biopharm. 2017;117:346–62.
Kumari M, Purohit MP, Patnaik S, et al. Curcumin loaded selenium nanoparticles synergize the anticancer potential of doxorubicin contained in self-assembled, cell receptor focused nanoparticles. Eur J Pharm Biopharm. 2018;130:185–99.
Zhang S, Ji X, Liu Z, et al. Bimetallic nanoplatforms for prostate most cancers remedy by interfering mobile communication. J Am Chem Soc. 2024;146(32):22530–40.
Wu J. The improved permeability and retention (EPR) impact: the importance of the idea and strategies to boost its software. J Pers Med. 2021;11(8):771.
Danhier F, Feron O, Préat V. To take advantage of the tumor microenvironment: Passive and energetic tumor focusing on of nanocarriers for anti-cancer drug supply. J Management Launch. 2010;148(2):135–46.
Muggia F, Kudlowitz D. Novel taxanes. Anticancer Medicine. 2014;25(5):593–8.
Tan L, Peng J, Zhao Q, et al. A novel MPEG-PDLLA-PLL copolymer for docetaxel supply in breast most cancers remedy. Theranostics. 2017;7(10):2652–72.
Xiao W, Suby N, Xiao Okay, et al. Extraordinarily lengthy tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian most cancers. J Management Launch. 2017;264:169–79.
He H, Liu L, Morin EE, et al. Survey of medical translation of most cancers nanomedicines—classes realized from successes and failures. Acc Chem Res. 2019;52(9):2445–61.
Youn YS, Bae YH. Views on the previous, current, and way forward for most cancers nanomedicine. Adv Drug Deliv Rev. 2018;130:3–11.
Wang Y, van Steenbergen MJ, Beztsinna N, et al. Biotin-decorated all-HPMA polymeric micelles for paclitaxel supply. J Management Launch. 2020;328:970–84.
Liu L, Deng Y, Zheng Z, et al. Hsp90 inhibitor STA9090 sensitizes hepatocellular carcinoma to hyperthermia-induced DNA injury by suppressing DNA-PKcs protein stability and mRNA transcription. Mol Most cancers Ther. 2021;20(10):1880–92.
Jia L, Yang H, Liu Y, et al. Focused supply of HSP90 inhibitors for environment friendly remedy of CD44-positive acute myeloid leukemia and strong tumor-colon most cancers. J Nanobiotechnol. 2024;22(1):198.
Sprint P, Piras AM, Sprint M. Cell membrane coated nanocarriers – an environment friendly biomimetic platform for focused remedy. J Management Launch. 2020;327:546–70.
Li H, Lu J, Yan C, et al. Tumor cell membrane-coated biomimetic nanoplatform for homologous focused remedy of colorectal carcinoma. Int J Polym Mater. 2019:1–10.
Baxevanis CN, Perez SA, Papamichail M. Most cancers immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167–89.
Yan S, Luo Z, Li Z, et al. Bettering most cancers immunotherapy outcomes utilizing biomaterials. Angew Chem Int Ed Engl. 2020;59(40):17332–43.
Sterner RC, Sterner RM. CAR-T cell remedy: present limitations and potential methods. Blood Most cancers J. 2021;11(4):69.
Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e168–78.
Martin JD, Cabral H, Stylianopoulos T, et al. Bettering most cancers immunotherapy utilizing nanomedicines: progress, alternatives and challenges. Nat Rev Clin Oncol. 2020;17(4):251–66.
Wang L, Xu H, Weng L, et al. Activation of most cancers immunotherapy by nanomedicine. Entrance Pharmacol. 2022;13:1041073.
Kennedy LB, Salama AKS. A evaluation of most cancers immunotherapy toxicity. CA Most cancers J Clin. 2020;70(2):86–104.
Liu YT, Solar ZJ. Turning chilly tumors into sizzling tumors by enhancing T-cell infiltration. Theranostics. 2021;11(11):5365–86.
Zhang Y, Zheng J. Features of immune checkpoint molecules past immune evasion. Adv Exp Med Biol. 2020;1248:201–26.
Sanaei MJ, Pourbagheri-Sigaroodi A, Kaveh V, et al. The applying of nano-medicine to beat the challenges associated to immune checkpoint blockades in most cancers immunotherapy: current advances and alternatives. Crit Rev Oncol Hematol. 2021;157: 103160.
Kapadia CH, Perry JL, Tian S, et al. Nanoparticulate immunotherapy for most cancers. J Management Launch. 2015;219:167–80.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. 5-year survival with mixed nivolumab and ipilimumab in superior melanoma. N Engl J Med. 2019;381(16):1535–46.
André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in beforehand handled sufferers with microsatellite instability-high/mismatch repair-deficient metastatic colorectal most cancers: 4-year follow-up from CheckMate 142. Ann Oncol. 2022;33(10):1052–60.
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in superior non-small-cell lung most cancers. N Engl J Med. 2019;381(21):2020–31.
Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic – a brand new method to most cancers remedy. Nat Rev Clin Oncol. 2023;20(4):265–78.
Bondeson DP, Mares A, Smith IE, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11(8):611–7.
Chen Y, Tandon I, Heelan W, et al. Proteolysis-targeting chimera (PROTAC) supply system: advancing protein degraders in the direction of medical translation. Chem Soc Rev. 2022;51(13):5330–50.
Yang L, Yang Y, Zhang J, et al. Sequential responsive nano-PROTACs for exact intracellular supply and enhanced degradation efficacy in colorectal most cancers remedy. Sign Transduct Goal Ther. 2024;9(1):275.
Gauthier J, Yakoub-Agha I. Chimeric antigen-receptor T-cell remedy for hematological malignancies and strong tumors: medical knowledge so far, present limitations and views. Curr Res Transl Med. 2017;65(3):93–102.
Kosti P, Maher J, Arnold JN. Views on chimeric antigen receptor T-cell immunotherapy for strong tumors. Entrance Immunol. 2018;9:1104.
Tang L, Zheng Y, Melo MB, et al. Enhancing T cell remedy by way of TCR-signaling-responsive nanoparticle drug supply. Nat Biotechnol. 2018;36(8):707–16.
Luo Y, Chen Z, Solar M, et al. IL-12 nanochaperone-engineered CAR T cell for strong tumor-immunotherapy. Biomaterials. 2022;281: 121341.
Sivaram AJ, Wardiana A, Howard CB, et al. Current advances within the technology of antibody-nanomaterial conjugates. Adv Healthc Mater. 2018;7(1):1.
Richards DA, Maruani A, Chudasama V. Antibody fragments as nanoparticle focusing on ligands: a step in the fitting route. Chem Sci. 2017;8(1):63–77.
Cheng Z, Al Zaki A, Hui JZ, et al. Multifunctional nanoparticles: price versus good thing about including focusing on and imaging capabilities. Science. 2012;338(6109):903–10.
Acharya S, Dilnawaz F, Sahoo SK. Focused epidermal development issue receptor nanoparticle bioconjugates for breast most cancers remedy. Biomaterials. 2009;30(29):5737–50.
Saniee F, Shabani Ravari N, Goodarzi N, et al. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate most cancers supply of docetaxel. Pharm Dev Technol. 2021;26(4):381–9.
Dhritlahre RK, Saneja A. Current advances in HER2-targeted supply for most cancers remedy. Drug Discov Right this moment. 2021;26(5):1319–29.
Nieto C, Vega MA, Martín Del Valle EM. Trastuzumab: greater than a information in HER2-positive most cancers nanomedicine. Nanomaterials. 2020;10(9):1.
Liu Y, Li Okay, Liu B, et al. A technique for precision engineering of nanoparticles of biodegradable copolymers for quantitative management of focused drug supply. Biomaterials. 2010;31(35):9145–55.
Abedin MR, Powers Okay, Aiardo R, et al. Antibody-drug nanoparticle induces synergistic remedy efficacies in HER2 constructive breast most cancers cells. Sci Rep. 2021;11(1):7347.
Gan J, Lei J, Li Y, et al. Manganese oxide-incorporated hybrid lipid nanoparticles amplify the efficiency of mrna vaccine by way of oxygen technology and STING activation. J Am Chem Soc. 2024;146(47):32689–700.
Rana PS, Ignatz-Hoover JJ, Guo C, et al. Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens, and enhances T-cell anti-myeloma exercise. Mol Most cancers Ther. 2024;23(12):1743–60.
Haist M, Mailänder V, Bros M. Nanodrugs focusing on T cells in tumor remedy. Entrance Immunol. 2022;13: 912594.
Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in most cancers: mechanistic foundation and therapeutic methods. Semin Most cancers Biol. 2015;35(Suppl):S185–98.
Tan Y, Chen H, Gou X, et al. Tumor vaccines: towards multidimensional anti-tumor therapies. Hum Vaccin Immunother. 2023;19(3):2271334.
Liu T, Yao W, Solar W, et al. Elements, formulations, deliveries, and combos of tumor vaccines. ACS Nano. 2024;18(29):18801–33.
Zhao Y, Track D, Wang Z, et al. Antitumour vaccination by way of the focused proteolysis of antigens remoted from tumour lysates. Nat Biomed Eng. 2024;9(2):234–48.
Hui L, Chen Y. Tumor microenvironment: sanctuary of the satan. Most cancers Lett. 2015;368(1):7–13.
Solar Y. Translational horizons within the tumor microenvironment: harnessing breakthroughs and focusing on cures. Med Res Rev. 2015;35(2):408–36.
Magnon C, Corridor SJ, Lin J, et al. Autonomic nerve growth contributes to prostate most cancers development. Science. 2013;341(6142):1236361.
Hanahan D, Monje M. Most cancers hallmarks intersect with neuroscience within the tumor microenvironment. Most cancers Cell. 2023;41(3):573–80.
Cervantes-Villagrana RD, Albores-García D, Cervantes-Villagrana AR, et al. Tumor-induced neurogenesis and immune evasion as targets of revolutionary anti-cancer therapies. Sign Transduct Goal Ther. 2020;5(1):99.
Nakagawara A. Trk receptor tyrosine kinases: a bridge between most cancers and neural growth. Most cancers Lett. 2001;169(2):107–14.
Li M, Zhou H, Yang C, et al. Bacterial outer membrane vesicles as a platform for biomedical functions: an replace. J Management Launch. 2020;323:253–68.
Qin J, Liu J, Wei Z, et al. Focused intervention in nerve–most cancers crosstalk enhances pancreatic most cancers chemotherapy.1–14.
Liu H, Zhu X, Wei Y, et al. Current advances in focused gene silencing and most cancers remedy by nanoparticle-based supply methods. Biomed Pharmacother. 2023;157: 114065.
Gujrati M, Vaidya AM, Mack M, et al. Focused twin pH-sensitive lipid ECO/siRNA self-assembly nanoparticles facilitate in vivo cytosolic sieIF4E supply and overcome paclitaxel resistance in breast most cancers remedy. Adv Healthc Mater. 2016;5(22):2882–95.
Tang Q, Liu J, Jiang Y, et al. Cell-selective messenger RNA supply and CRISPR/Cas9 genome enhancing by modulating the interface of phenylboronic acid-derived lipid nanoparticles and mobile floor sialic acid. ACS Appl Mater Interfaces. 2019;11(50):46585–90.
Chen Z, Xiong M, Tian J, et al. Encapsulation and evaluation of therapeutic cargo in engineered exosomes: a scientific evaluation. J Nanobiotechnol. 2024;22(1):18.
Cheng Z, Li M, Dey R, et al. Nanomaterials for most cancers remedy: present progress and views. J Hematol Oncol. 2021;14(1):85.
Hadla M, Palazzolo S, Corona G, et al. Exosomes improve the therapeutic index of doxorubicin in breast and ovarian most cancers mouse fashions. Nanomedicine. 2016;11(18):2431–41.
Zhuo Y, Luo Z, Zhu Z, et al. Direct cytosolic supply of siRNA by way of cell membrane fusion utilizing cholesterol-enriched exosomes. Nat Nanotechnol. 2024;19(12):1858–68.
Osaki T, Yokoe I, Sunden Y, et al. Efficacy of 5-aminolevulinic acid in photodynamic detection and photodynamic remedy in veterinary medication. Cancers. 2019;11(4):5.
Zhuo X, Liu Z, Aishajiang R, et al. Current progress of copper-based nanomaterials in tumor-targeted photothermal remedy/photodynamic remedy. Pharmaceutics. 2023;15(9):1.
Qin L, Yan P, Xie C, et al. Gold nanorod-assembled ZnGa(2)O(4): Cr nanofibers for LED-amplified gene silencing in most cancers cells. Nanoscale. 2018;10(28):13432–42.
Franskevych D, Prylutska S, Grynyuk I, et al. Mode of photoexcited C(60) fullerene involvement in potentiating cisplatin toxicity in opposition to drug-resistant L1210 cells. Bioimpacts. 2019;9(4):211–7.
Grebinyk A, Prylutska S, Chepurna O, et al. Synergy of chemo- and photodynamic therapies with C(60) fullerene-doxorubicin nanocomplex. Nanomaterials. 2019;9(11):1.
Liu J, Zhu C, Xu L, et al. Nanoenabled intracellular calcium bursting for protected and environment friendly reversal of drug resistance in tumor cells. Nano Lett. 2020;20(11):8102–11.
Higgins CF. A number of molecular mechanisms for multidrug resistance transporters. Nature. 2007;446(7137):749–57.
Zou J, Xing X, Teng C, et al. Cocrystal@protein-anchoring nanococktail for combinatorially treating multidrug-resistant most cancers. Acta Pharm Sin B. 2024;14(10):4509–25.
Patel NR, Pattni BS, Abouzeid AH, et al. Nanopreparations to beat multidrug resistance in most cancers. Adv Drug Deliv Rev. 2013;65(13–14):1748–62.
Zheng Y, Su C, Zhao L, et al. mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance by way of two potential therapeutic targets modulation of MDR1 and autophagy. J Nanobiotechnol. 2017;15(1):66.
Levy JMM, Towers CG, Thorburn A. Concentrating on autophagy in most cancers. Nat Rev Most cancers. 2017;17(9):528–42.
Ma Z, Lin Okay, Tang M, et al. A pH-driven small-molecule nanotransformer hijacks lysosomes and overcomes autophagy-induced resistance in most cancers. Angew Chem Int Ed Engl. 2022;61(35): e202204567.
World, regional, and nationwide deaths, prevalence, disability-adjusted life years, and years lived with incapacity for persistent obstructive pulmonary illness and bronchial asthma, 1990–2015: a scientific evaluation for the World Burden of Illness Examine 2015. Lancet Respir Med. 2017;5(9):691–706.
Forest V, Pourchez J. Nano-delivery to the lung – by inhalation or different routes and why nano when micro is basically ample? Adv Drug Deliv Rev. 2022;183: 114173.
Zhou QT, Leung SS, Tang P, et al. Inhaled formulations and pulmonary drug supply methods for respiratory infections. Adv Drug Deliv Rev. 2015;85:83–99.
Jin Z, Gao Q, Wu Okay, et al. Harnessing inhaled nanoparticles to beat the pulmonary barrier for respiratory illness remedy. Adv Drug Deliv Rev. 2023;202: 115111.
Ngan CL, Asmawi AA. Lipid-based pulmonary supply system: a evaluation and future concerns of formulation methods and limitations. Drug Deliv Transl Res. 2018;8(5):1527–44.
Joshi Okay, Chandra A, Jain Okay, et al. Nanocrystalization: an rising expertise to boost the bioavailability of poorly soluble medicine. Pharm Nanotechnol. 2019;7(4):259–78.
Ahmad J, Akhter S, Rizwanullah M, et al. Nanotechnology-based inhalation remedies for lung most cancers: state-of-the-art. Nanotechnol Sci Appl. 2015;8:55–66.
Peng S, Wang W, Zhang R, et al. Nano-formulations for pulmonary supply: previous, current, and future views. Pharmaceutics. 2024;16(2):4.
Golia A, Mahmood BR, Fundora Y, et al. Amikacin Liposome Inhalation Suspension for Mycobacterium avium Advanced Lung Illness. Sr Care Pharm. 2020; 35(4): 162–70.
Ziaei E, Emami J, Rezazadeh M, et al. Pulmonary supply of docetaxel and celecoxib by PLGA porous microparticles for his or her synergistic results in opposition to lung most cancers. Anticancer Brokers Med Chem. 2022;22(5):951–67.
Campbell NRC, Ordunez P, Giraldo G, et al. WHO HEARTS: a world program to cut back heart problems burden: expertise implementing within the Americas and alternatives in Canada. Can J Cardiol. 2021;37(5):744–55.
Wang H, Hsu JC, Track W, et al. Nanorepair medication for remedy of organ harm. Natl Sci Rev. 2024;11(9):nwae280.
Elsabahy M, Heo GS, Lim SM, et al. Polymeric nanostructures for imaging and remedy. Chem Rev. 2015;115(19):10967–1011.
Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a brand new class of distinction brokers for MR imaging. Radiology. 1990;175(2):489–93.
Lanza GM, Wallace KD, Scott MJ, et al. A novel site-targeted ultrasonic distinction agent with broad biomedical software. Circulation. 1996;94(12):3334–40.
Lanza GM, Wallace KD, Fischer SE, et al. Excessive-frequency ultrasonic detection of thrombi with a focused distinction system. Ultrasound Med Biol. 1997;23(6):863–70.
Park D, Cho Y, Goh SH, et al. Hyaluronic acid-polypyrrole nanoparticles as pH-responsive theranostics. Chem Commun. 2014;50(95):15014–7.
Qin J, Peng Z, Li B, et al. Gold nanorods as a theranostic platform for in vitro and in vivo imaging and photothermal remedy of inflammatory macrophages. Nanoscale. 2015;7(33):13991–4001.
Kang S, Lee HW, Jeon YH, et al. Mixed fluorescence and magnetic resonance imaging of major macrophage migration to websites of acute irritation utilizing near-infrared fluorescent magnetic nanoparticles. Mol Imaging Biol. 2015;17(5):643–51.
Huang Y, Li L, Zhang D, et al. Gadolinium-doped carbon quantum dots loaded magnetite nanoparticles as a bimodal nanoprobe for each fluorescence and magnetic resonance imaging. Magn Reson Imaging. 2020;68:113–20.
Bruckman MA, Jiang Okay, Simpson EJ, et al. Twin-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo utilizing VCAM-1 focused tobacco mosaic virus. Nano Lett. 2014;14(3):1551–8.
Kwon SP, Jeon S, Lee SH, et al. Thrombin-activatable fluorescent peptide included gold nanoparticles for twin optical/computed tomography thrombus imaging. Biomaterials. 2018;150:125–36.
Wu Q, Pan W, Wu G, et al. CD40-targeting magnetic nanoparticles for MRI/optical dual-modality molecular imaging of weak atherosclerotic plaques. Atherosclerosis. 2023;369:17–26.
Tao Y, Lan X, Zhang Y, et al. Biomimetic nanomedicines for exact atherosclerosis theranostics. Acta Pharm Sin B. 2023;13(11):4442–60.
McCarthy JR, Korngold E, Weissleder R, et al. A lightweight-activated theranostic nanoagent for focused macrophage ablation in inflammatory atherosclerosis. Small. 2010;6(18):2041–9.
Lobatto ME, Fayad ZA, Silvera S, et al. Multimodal medical imaging to longitudinally assess a nanomedical anti-inflammatory remedy in experimental atherosclerosis. Mol Pharm. 2010;7(6):2020–9.
Iverson NM, Plourde NM, Sparks SM, et al. Twin use of amphiphilic macromolecules as ldl cholesterol efflux triggers and inhibitors of macrophage athero-inflammation. Biomaterials. 2011;32(32):8319–27.
Tavares ER, Freitas FR, Diament J, et al. Discount of atherosclerotic lesions in rabbits handled with etoposide related to cholesterol-rich nanoemulsions. Int J Nanomed. 2011;6:2297–304.
Wu Z, Chen C, Zhang B, et al. EGFP-EGF1-conjugated poly(lactic-co-glycolic acid) nanoparticles, a brand new diagnostic device and drug provider for atherosclerosis. Int J Nanomed. 2019;14:2609–18.
Zhao Y, Imura T, Leman LJ, et al. Mimicry of high-density lipoprotein: purposeful peptide-lipid nanoparticles primarily based on multivalent peptide constructs. J Am Chem Soc. 2013;135(36):13414–24.
Shin MD, Ortega-Rivera OA, Steinmetz NF. Multivalent show of ApoAI peptides on the floor of tobacco mosaic virus nanotubes improves ldl cholesterol efflux. Bioconjug Chem. 2022;33(10):1922–33.
Mu D, Li J, Qi Y, et al. Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for assuaging atherosclerosis. J Nanobiotechnol. 2020;18(1):179.
Xie S, Mo C, Cao W, et al. Micro organism-propelled microtubular motors for environment friendly penetration and focusing on supply of thrombolytic brokers. Acta Biomater. 2022;142:49–59.
Xie DM, Zhong Q, Xu X, et al. Alpha lipoic acid-loaded electrospun fibrous patch movies defend coronary heart in acute myocardial infarction mice by inhibiting oxidative stress. Int J Pharm. 2023;632: 122581.
Li H, Zhu J, Xu YW, et al. Notoginsenoside R1-loaded mesoporous silica nanoparticles focusing on the positioning of harm by way of inflammatory cells improves coronary heart restore after myocardial infarction. Redox Biol. 2022;54: 102384.
Lan M, Hou M, Yan J, et al. Cardiomyocyte-targeted anti-inflammatory nanotherapeutics in opposition to myocardial ischemia reperfusion (IR) harm. Nano Res. 2022;15(10):9125–34.
Bajaj A, Rao MR, Pardeshi A, et al. Nanocrystallization by evaporative antisolvent method for solubility and bioavailability enhancement of telmisartan. AAPS PharmSciTech. 2012;13(4):1331–40.
Rachmawati H, Soraya IS, Kurniati NF, et al. In vitro examine on antihypertensive and antihypercholesterolemic results of a curcumin nanoemulsion. Sci Pharm. 2016;84(1):131–40.
Southgate L, Machado RD, Gräf S, et al. Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol. 2020;17(2):85–95.
Spiekerkoetter E, Kawut SM, de Jesus Perez VA. New and rising therapies for pulmonary arterial hypertension. Annu Rev Med. 2019;70:45–59.
Teng C, Li B, Lin C, et al. Focused supply of baicalein-p53 complicated to easy muscle cells reverses pulmonary hypertension. J Management Launch. 2022;341:591–604.
Vani JR, Mohammadi MT, Foroshani MS, et al. Polyhydroxylated fullerene nanoparticles attenuate mind infarction and oxidative stress in rat mannequin of ischemic stroke. Excli j. 2016;15:378–90.
Choudhury AA, Devi RV. Gestational diabetes mellitus—a metabolic and reproductive dysfunction. Biomed Pharmacother. 2021;143: 112183.
Bolli GB, Porcellati F, Lucidi P, et al. The physiological foundation of insulin remedy in folks with diabetes mellitus. Diabetes Res Clin Pract. 2021;175: 108839.
Sarkar S, Ekbal Kabir M, Kalita J, et al. Mesoporous silica nanoparticles: drug supply automobiles for antidiabetic molecules. ChemBioChem. 2023;24(7): e202200672.
Li X, Peng X, Zoulikha M, et al. Multifunctional nanoparticle-mediated combining remedy for human illnesses. Sign Transduct Goal Ther. 2024;9(1):1.
Hunt NJ, Lockwood GP, Heffernan SJ, et al. Oral nanotherapeutic formulation of insulin with decreased episodes of hypoglycaemia. Nat Nanotechnol. 2024;19(4):534–44.
Xu B, Jiang G, Yu W, et al. H(2)O(2)-responsive mesoporous silica nanoparticles built-in with microneedle patches for the glucose-monitored transdermal supply of insulin. J Mater Chem B. 2017;5(41):8200–8.
Shrestha N, Araújo F, Shahbazi MA, et al. Oral hypoglycaemic impact of GLP-1 and DPP4 inhibitor primarily based nanocomposites in a diabetic animal mannequin. J Management Launch. 2016;232:113–9.
Rocha S, Lucas M, Ribeiro D, et al. Nano-based drug supply methods used as automobiles to boost polyphenols therapeutic impact for diabetes mellitus remedy. Pharmacol Res. 2021;169: 105604.
Zhang J, Zhou J, Zhang T, et al. Facile fabrication of an amentoflavone-loaded micelle system for oral supply to enhance bioavailability and hypoglycemic results in KKAy mice. ACS Appl Mater Interfaces. 2019;11(13):12904–13.
Chen H, Khemtong C, Yang X, et al. Nanonization methods for poorly water-soluble medicine. Drug Discovery Right this moment. 2011;16(7):354–60.
Goyal R, Macri LK, Kaplan HM, et al. Nanoparticles and nanofibers for topical drug supply. J Management Launch. 2016;240:77–92.
Güngör S, Kahraman E. Nanocarriers mediated cutaneous drug supply. Eur J Pharm Sci. 2021;158: 105638.
Ren J, Liu T, Bi B, et al. Growth and analysis of tacrolimus loaded nano-transferosomes for pores and skin focusing on and dermatitis remedy. J Pharm Sci. 2024;113(2):471–85.
Fratoddi I, Benassi L, Botti E, et al. Results of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse mannequin. Nanomedicine. 2019;17:276–86.
Moazeni M, Kelidari HR, Saeedi M, et al. Time to beat fluconazole resistant Candida isolates: strong lipid nanoparticles as a novel antifungal drug supply system. Colloids Surf B Biointerfaces. 2016;142:400–7.
Dong P, Sahle FF, Lohan SB, et al. pH-sensitive Eudragit® L 100 nanoparticles promote cutaneous penetration and drug launch on the pores and skin. J Management Launch. 2019;295:214–22.
Xiao Q, Lu Y, Yao W, et al. Molybdenum nanoparticles as a possible topical medicine for alopecia remedy by way of antioxidant pathways that differ from minoxidil. J Hint Elem Med Biol. 2024;82: 127368.
Taylor AW. Ocular immune privilege. Eye. 2009;23(10):1885–9.
Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug supply. Aaps j. 2010;12(3):348–60.
Chakraborty M, Banerjee D, Mukherjee S, et al. Exploring the development of polymer-based nano-formulations for ocular drug supply methods: an explicative evaluation. Polym Bull. 2023;80:11759–77.
Li Okay, Lin M, Huang Okay, et al. Therapeutic impact and mechanism of motion of pterostilbene nano medicine in dry eye fashions. Exp Eye Res. 2024;241: 109836.
Cui W, Chen S, Hu T, et al. Nanoceria-mediated cyclosporin a supply for dry eye illness administration by way of modulating immune-epithelial crosstalk. ACS Nano. 2024;18(17):11084–102.
Hakim A, Guido B, Narsineni L, et al. Gene remedy methods for glaucoma from IOP discount to retinal neuroprotection: progress in the direction of non-viral methods. Adv Drug Deliv Rev. 2023;196: 114781.
Zhou X, Rong R, Liang G, et al. Self-assembly hypoxic and ROS twin response nano prodrug as a brand new therapeutic method for glaucoma remedies. Adv Sci. 2024;11(41): e2407043.
Maulvi FA, Desai DT, Shetty KH, et al. Advances and challenges within the nanoparticles-laden contact lenses for ocular drug supply. Int J Pharm. 2021;608: 121090.
Maulvi FA, Soni PD, Patel PJ, et al. Managed bimatoprost launch from graphene oxide laden contact lenses: In vitro and in vivo research. Colloids Surf B Biointerfaces. 2021;208: 112096.
Ando H, Abu Lila AS, Kawanishi M, et al. Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes in opposition to auto and international antigens. J Management Launch. 2018;270:114–9.
Berndt A, Lee SY, Ramakrishnan C, et al. Construction-guided transformation of channelrhodopsin right into a light-activated chloride channel. Science. 2014;344(6182):420–4.
Zhou Y, Cai G, Wang Y, et al. Microarray chip-based high-throughput screening of neurofilament mild chain self-assembling peptide for noninvasive monitoring of Alzheimer’s illness. ACS Nano. 2024;18(28):18160–75.
Witten J, Raji I, Manan RS, et al. Synthetic intelligence-guided design of lipid nanoparticles for pulmonary gene remedy. Nat Biotechnol. 2024. https://doi.org/10.1038/s41587-024-02490-y.